CNS Pharmaceuticals Reports Q2 2024 Results and Advances Cancer Treatment Research
CNS Pharmaceuticals has released its Q2 2024 financial results and provided updates on its cancer treatment research, including progress on Berubicin for glioblastoma and plans for TPI 287 development.
Read the full story























